4Karlowsky JA, Thomsberry C, Jones ME,et al. Factors associated with relative rates of antimierobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998--2002). Clin Infect Dis, 2003,36: 963-970.
5Adam HJ, Schurek KN, Nichol KA, et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother,2007,51 : 198-207.
6中华人民共和国卫生部办公厅.关于进一步加强抗菌药物临床应用管理的通知.2008-04-15.
7Ramirez J A, Mgayen T.Treating community-acqured pneumonia with once- daily gatifloxacin VS twice-daily clarithromycin. J Respir Dis, 1999, 20:s60-69.
8Forrest A, Nix DE,Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother, 1993, 37:1073-1081
9Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis , 1998, 27:33-39.
10Dalnoff A. Pharmacodymics of fluoquinolones. J Antimicrob Chemother, 1999, 43:51-59.
